Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Wednesday July io

Oral Sessions 14:oo - 15: 30

B09 ]Emerging Toxicity of Antiretoviral Therapy
Oral Abstract Session
Venue: Hall 2:1
Date: Wednesday, July 10, 2002
Time: 14:00- 15:30
Chairs: lan Weller, United Kingdom
Pere Domingo, Spain

[ BIO ]Rapid and Novel Laboratory Tests

Venue:
Date:
Time:
Chairs:

Oral Abstract Session
Hall Verdi
Wednesday, July 10, 2002
14:00oo - 15:30
Kiat Ruxrungtham, Thailand
Tomas Pumarola, Spain

14:00oo WeOrBl3o3

14:15 WeOrBl3o4
14:3o WeOrBl3o5
14:45 WeOrBl3o6
15:oo WeOrBl3o7
15:15 WeOrB2o3

Frequency, type, severity, and duration of
adverse drug events on highly-active
antiretroviral therapy (HAART) in a
resource-poor setting
H Reuter, T Kasper, C Poole, V Skefile,
E Goemaere (South Africa)
Preserved mitochondrial/nuclear (mt/n)
DNA ratios in peripheral blood cells from
HIV-infected individuals on stavudinesparing regimens
H C F Cote, B Yip, ]W Chan,
Z L Brumme, R S Hogg, PR Harrigan,
M V O'Shaughnessy, I Montaner
(Canada)
Decline of mitochondrial DNA during
therapy with nucleoside analogue
reverse transcriptase inhibitors assessed
by a single-tube NASBA simultaneously
assaying both mitochondrial and nuclear
DNA
A de Ronde B van Gemen, M Casula,
E Timmermans, M van Dooren,
M Westrop, I Dobbelaer, M Bakker,
G J Weverling, I Lange, JGoudsmit,
P Reiss (The Netherlands)
Fat redistribution and metabolic changes
with a nucleoside-reverse transcriptase
inhibitor (NRTI), non-NRTI, or protease
inhibitor-based regimen: FRAMS
substudy of the Atlantic study
R L Murphy1, C Katlama2,
G J Weverling3, F Hoffp, B Berzins1,
J Gatell4, A Horban5, A van Eeden3,
FAntunes6, S Staszewski7, B Clotet4,
E Bijleveld3 (lUnited States; 2France;
3The Netherlands; 4Spain; 5Poland;
6Portugal; Z7Germany)
Incidence of coronary artery disease in
HIV-infected patients receiving or not
protease inhibitors: a randomized,
multicenter study
G Barbaro, G Di Lorenzo, G Giancaspro,
A M Pellicelli, B Grisorio, G Barbarini (Italy)
Perspective of HIV-associated coronary
heart disease
Jens D Lundqren (Denmark)

14:00oo WeOrB'338
14:15 WeOrB1339
14:30 WeOrBl34o
14:45 WeOrB1341
15:oo WeOrB1342
15:15 WeOrB1343

Quantitation of HIV-1 subtypes by the
VIDAS PROBE qHIV test
P I Levasseur, D W Eustace, I M McCarty,
I L Burg (United States)
Use of dried blood spots for diagnosis
and viral quantification in perinatal HIV-1
infection in Thailand
T Chaowanachan', K Chokephaibulkit,
T Chotpitayasunondh', P Wasinrapee1,
A Teeraratkul, B jetsawang,
K Neeyapun, R jSimonds2, N L Young'
(0Thailand; 2United States)
HIV-1 p24 antigen, an inexpensive
alternative viral load marker, is an
independent correlate of CD4 T-cell
changes in patients on successful longterm antiretroviral therapy
J SchUpbach, J Bni, Z Tomasik,
L Bisset, M Fischer, H Ganthard,
B Ledergerber, M Opravil (Switzerland)
Evaluation of an ultrasensitive p24
antigen assay (UPTA) as a possible
surrogate marker of HIV-1 RNA in
resource-poor settings
R Respess', A Cachafeiro, D Withum,
S Fiscus', D Newman', I Cabruja',
B Branson', 0 Varnier2, T Dondero
(lUnited States; 2Italy)
Successful implementation in West
African laboratories of an alternative
method to accurately enumerate at lower
cost circulating CD4+ T lymphocytes in
HIV-infected patients
S Diabouc7l, C Chazallon,
M D Kazatchkine, P Van de Perre, Wednesday
A Inwoley, S M'boup4, M Prince David5,
A Tioro6, R Soudrd1, I P Aboulker2,
L Weiss2 (Burkina Faso; 2France;
3Cote d'Ivoire; 4Senegal; 5Togo; 6Mal)
Development of affordable and portable
HIV and CD4 diagnostic tests using
microchips
W R Rodriquez N Christodoulides,
M Ali, M Rodriguez, P Floriano,
N Bono, B D Walker, JT McDevitt
(United States)

XIV International AIDS Conference BARCELONA - JULY 7-12

141